SARAH ROOKER: Open Payments
NPI 1013685494 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,436 in 109 payments from 18 companies in 2025. Trend: 2023 $2,523 · 2024 $2,720 · 2025 $2,436
Food & beverage: $2,436
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $495 |
| Madrigal Pharmaceuticals | 19 | $406 |
| Gilead Sciences, Inc. | 8 | $275 |
| Ipsen Biopharmaceuticals, Inc | 6 | $209 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $159 |
| Celltrion USA Inc. | 7 | $144 |
| Ardelyx, Inc. | 2 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $140 |
| Janssen Biotech, Inc. | 5 | $107 |
| Lilly USA, LLC | 3 | $76 |
Products named: REZDIFFRA, IQIRVO, SKYRIZI, XIFAXAN, VEGZELMA, IBSRELA, ENTYVIO, RINVOQ.
Industry payments across KS — which companies pay providers there.
